亿胜生物科技(01061.HK)干眼症新药取得顶线第一阶段Ⅱ期临床数据
格隆汇7月19日丨亿胜生物科技(01061.HK)宣布,有关干眼症的美国药监局第一阶段三期临床试验中已取得显示有关该产品功效及安全性的临床相关体征及症状的正面顶线数据,该产品为含SkQ1的滴眼液,SkQ1作为其唯一活性药物成分,将提供为干眼症领域的药品。第一阶段三期试验乃以约450名就诊患者为基础,彼等于约9周期间内接受治疗。
鉴于第一阶段三期试验中取得的正面试验数据,EssexBio-Investment与Mitotech正就将该产品的美国药监局三期临床试验推进至下一阶段(即第二阶段三期临床试验)进行讨论。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.